Key Takeaways
- • BioStack, a healthcare technology company, raised $9.5 million in seed funding led by Peak XV, Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures, and Y Combinator.
- • The company is launching a data infrastructure network spanning the U.S., India, Brazil, and Argentina with over 100 million de-identified patient records.
- • BioStack aggregates fragmented clinical information into longitudinal patient records covering notes, labs, imaging, medications, treatment, and outcomes to supply AI and biotech developers with training data.
- • Proceeds will fund geographic expansion, platform development, and growth of engineering and research teams.
Summary
BioStack, a San Francisco-based healthcare technology company, announced $9.5 million in seed funding, with the round led by Peak XV, Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures, and Y Combinator. The company said the capital will support its continued expansion across the United States and international markets, development of its technology platform, and growth of its engineering and research teams.
Alongside the funding, BioStack announced the launch of a data infrastructure network intended to power the next phase of medicine. According to the company, the network spans the U.S., India, Brazil, and Argentina and contains more than 100 million de-identified patient records. BioStack positions the network as a means of connecting fragmented clinical information so that AI and biotechnology companies can train models on how disease progresses, how treatments work, and what drives patient outcomes.
The company describes its core function as building data infrastructure for healthcare and medical AI. It links information across healthcare systems to create longitudinal patient records that combine clinical notes, laboratory results, imaging, medications, and treatment and outcome data. BioStack then de-identifies this information to produce proprietary datasets intended to support healthcare research, biotechnology development, and the evaluation of medical AI tools.
Alongside the funding, BioStack announced the launch of a data infrastructure network intended to power the next phase of medicine. According to the company, the network spans the U.S., India, Brazil, and Argentina and contains more than 100 million de-identified patient records. BioStack positions the network as a means of connecting fragmented clinical information so that AI and biotechnology companies can train models on how disease progresses, how treatments work, and what drives patient outcomes.
The company describes its core function as building data infrastructure for healthcare and medical AI. It links information across healthcare systems to create longitudinal patient records that combine clinical notes, laboratory results, imaging, medications, and treatment and outcome data. BioStack then de-identifies this information to produce proprietary datasets intended to support healthcare research, biotechnology development, and the evaluation of medical AI tools.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.